PE20170470A1 - Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes - Google Patents
Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetesInfo
- Publication number
- PE20170470A1 PE20170470A1 PE2017000004A PE2017000004A PE20170470A1 PE 20170470 A1 PE20170470 A1 PE 20170470A1 PE 2017000004 A PE2017000004 A PE 2017000004A PE 2017000004 A PE2017000004 A PE 2017000004A PE 20170470 A1 PE20170470 A1 PE 20170470A1
- Authority
- PE
- Peru
- Prior art keywords
- prevent
- promote
- treat
- diabetes
- development
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 230000004580 weight loss Effects 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a una composicion farmaceutica que comprende un desacoplador quimico tal como tirfostina 9, en una cantidad de 2mg a 200 mg y L-carnitina o un derivado de la misma, en una cantidad de 20 mg a 5000 mg. Adicionalmente, dicha composicion se puede combinar con uno o mas agentes terapeuticos tal como insulina, sulfonilureas, biguanidas, entre otros. Dicha composicion es util en el tratamiento de la obesidad, prevencion del aumento de peso, promover la perdida de peso o tratar y prevenir el desarrollo de diabetes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020797P | 2014-07-03 | 2014-07-03 | |
| US201562127111P | 2015-03-02 | 2015-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170470A1 true PE20170470A1 (es) | 2017-05-14 |
Family
ID=55016229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000004A PE20170470A1 (es) | 2014-07-03 | 2015-07-02 | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10849872B2 (es) |
| EP (1) | EP3164125B8 (es) |
| JP (2) | JP6887252B2 (es) |
| CN (2) | CN113387836A (es) |
| AU (2) | AU2015283905B2 (es) |
| BR (1) | BR112016030983A8 (es) |
| CA (1) | CA2954004C (es) |
| CO (1) | CO2017001025A2 (es) |
| DK (1) | DK3164125T3 (es) |
| ES (1) | ES2965033T3 (es) |
| FI (1) | FI3164125T3 (es) |
| HR (1) | HRP20231572T1 (es) |
| HU (1) | HUE064714T2 (es) |
| MX (2) | MX388834B (es) |
| PE (1) | PE20170470A1 (es) |
| PT (1) | PT3164125T (es) |
| RU (1) | RU2745440C2 (es) |
| SM (1) | SMT202300445T1 (es) |
| WO (1) | WO2016004363A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| BR112019010607B1 (pt) * | 2016-11-29 | 2023-10-31 | University Of Iowa Research Foundation | Uso de precursores de nad e composição compreendendo os referidos precursores |
| MY192778A (en) | 2017-01-06 | 2022-09-08 | Rivus Pharmaceuticals Inc | Novel phenyl derivatives |
| CN107212225A (zh) * | 2017-06-02 | 2017-09-29 | 陈玉霞 | 一种用于瘦身的玫瑰茄固体饮料及其制备方法 |
| US10226442B2 (en) * | 2017-07-10 | 2019-03-12 | Syneurx International (Taiwan) Corp. | Lithium salts of N-substituted glycine compounds and uses thereof |
| WO2019083297A1 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 네비팜 | 간질환 예방 또는 치료용 의약 조성물 |
| CN108272903A (zh) * | 2018-03-15 | 2018-07-13 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种减肥配方及其应用方法 |
| US12285456B2 (en) | 2018-03-20 | 2025-04-29 | Exerkine Corporation | Weight management composition |
| CA3050823C (en) * | 2018-03-20 | 2021-02-23 | Mark TARNOPOLSKY | Weight management composition |
| TWI710766B (zh) * | 2018-08-13 | 2020-11-21 | 國立臺灣大學 | 使用口服肉鹼耐量試驗以測定一個體內氧化三甲胺產能之檢測方法 |
| JP2024534132A (ja) * | 2021-08-25 | 2024-09-18 | ガルシア・サダ，フェルナンド | メタボリックシンドロームのリスクの予防又は低減のための組成物及び方法 |
| US20230266340A1 (en) * | 2022-02-24 | 2023-08-24 | Fernando García Sada | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome |
| CN118104816A (zh) * | 2022-11-30 | 2024-05-31 | 武汉蜜欢健康产业发展有限公司 | 食用组合物及其应用 |
| CN118542463B (zh) * | 2024-07-25 | 2024-11-12 | 浙江衡美健康科技股份有限公司 | 快速减重的高脂肪组合物、制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| IT1156852B (it) | 1978-07-10 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Procedimento industriale per la preparazione del d'canforato della l carnitinammide e del d canforato della d carnitinammide e sue applicazioni |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| DE3463261D1 (en) | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| AU632992B2 (en) | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
| IT1256705B (it) | 1992-12-21 | 1995-12-12 | Sigma Tau Ind Farmaceuti | Procedimento per la preparazione di l-(-)-carnitina a partire da un prodotto di scarto avente opposta configurazione. |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| CA2383814C (en) | 1999-09-03 | 2010-08-17 | Sigma-Tau Healthscience S.P.A. | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| DE10055940A1 (de) * | 2000-11-10 | 2002-05-29 | Bayer Ag | Neue Indanylidenverbindungen |
| EP1575575B1 (en) * | 2002-11-08 | 2010-05-19 | High Point Pharmaceuticals, LLC | Safe chemical uncouplers for the treatment of obesity |
| WO2005089567A1 (en) * | 2004-03-17 | 2005-09-29 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
| US7691578B2 (en) * | 2004-07-07 | 2010-04-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating obesity |
| RU2342115C2 (ru) * | 2006-12-28 | 2008-12-27 | Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ТНИИКиФ Росздрава) | Способ комплексного лечения детей с ожирением |
| WO2010022236A2 (en) * | 2008-08-20 | 2010-02-25 | The University Of Medicine And Dentistry Of New Jersey | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor |
-
2015
- 2015-07-02 HR HRP20231572TT patent/HRP20231572T1/hr unknown
- 2015-07-02 EP EP15815585.3A patent/EP3164125B8/en active Active
- 2015-07-02 CN CN202110646408.6A patent/CN113387836A/zh active Pending
- 2015-07-02 SM SM20230445T patent/SMT202300445T1/it unknown
- 2015-07-02 MX MX2017000222A patent/MX388834B/es unknown
- 2015-07-02 FI FIEP15815585.3T patent/FI3164125T3/fi active
- 2015-07-02 CN CN201580047257.5A patent/CN106604725B/zh active Active
- 2015-07-02 RU RU2017103450A patent/RU2745440C2/ru active
- 2015-07-02 DK DK15815585.3T patent/DK3164125T3/da active
- 2015-07-02 CA CA2954004A patent/CA2954004C/en active Active
- 2015-07-02 JP JP2016576053A patent/JP6887252B2/ja active Active
- 2015-07-02 PE PE2017000004A patent/PE20170470A1/es unknown
- 2015-07-02 PT PT158155853T patent/PT3164125T/pt unknown
- 2015-07-02 WO PCT/US2015/039075 patent/WO2016004363A2/en not_active Ceased
- 2015-07-02 HU HUE15815585A patent/HUE064714T2/hu unknown
- 2015-07-02 US US14/790,824 patent/US10849872B2/en active Active
- 2015-07-02 BR BR112016030983A patent/BR112016030983A8/pt not_active Application Discontinuation
- 2015-07-02 AU AU2015283905A patent/AU2015283905B2/en active Active
- 2015-07-02 ES ES15815585T patent/ES2965033T3/es active Active
-
2017
- 2017-01-04 MX MX2021015661A patent/MX2021015661A/es unknown
- 2017-02-03 CO CONC2017/0001025A patent/CO2017001025A2/es unknown
-
2020
- 2020-04-09 JP JP2020070284A patent/JP7171644B2/ja active Active
- 2020-11-30 US US17/106,908 patent/US20210186918A1/en not_active Abandoned
-
2021
- 2021-01-20 AU AU2021200355A patent/AU2021200355B2/en active Active
-
2023
- 2023-10-23 US US18/382,997 patent/US20240066001A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170470A1 (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
| CL2019001565A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX384264B (es) | Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo | |
| EA201890641A3 (ru) | Стимуляторы sgc | |
| AR093386A1 (es) | Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
| ECSP10010589A (es) | Farmaco contra el cancer de higado | |
| MX2018015657A (es) | Compuestos heterociclico como antibacterianos. | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| MX2019006893A (es) | Inhibidores heterociclicos de mct4. | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2017001025A1 (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| MX2017002948A (es) | Métodos de tratamiento para la sarcoidosis pulmonar. | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| AR103323A1 (es) | Derivados de glucagón |